Niagen Bioscience has received key regulatory designations in the United States and European Union for NB4168, an investigational small molecule therapy for ataxia telangiectasia (A‑T), a rare pediatric neurodegenerative disease with no approved treatments.
The FDA granted Rare Pediatric Disease (RPD) designation to NB4168 for A‑T, recognizing the condition as a serious, life‑threatening disorder that primarily affects children and meets criteria for rarity. In parallel, the European Medicines Agency’s Committee for Orphan Medicinal Products awarded Orphan Medicinal Product Designation (OMPD) for NB4168 in A‑T, providing development incentives intended to support therapies in underserved rare diseases.
NB4168 is an oral small molecule engineered to deliver substantially higher exposure to nicotinamide riboside (NR) than conventional formulations, while maintaining a differentiated pharmacokinetic and safety profile. The candidate is designed to boost NAD+, a coenzyme involved in DNA repair, mitochondrial function, cellular energy production, and stress responses—pathways disrupted in A‑T and other conditions characterized as premature aging diseases.
The therapy is the first clinical-stage asset from Niagen’s NAD Pharmaceuticals subsidiary, which focuses on rare genetic diseases and age‑related disorders. Company leadership said the dual U.S. and EU designations represent regulatory validation of its development strategy and strengthen the path toward clinical studies of NB4168.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!